Drug intelligence / Profile preview

lactobacillus acidophilus NCFM + lactobacillus paracasei Lpc-37 + bifidobacterium lactis Bi-04 + bifidobacterium lactis Bi-07 + bifidobacterium bifidum Bb-02

Development stage: Unknown
Lead developer: International Flavors & Fragrances
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This investigational live biotherapeutic product (LBP) is a specific five-strain probiotic blend consisting of *Lactobacillus acidophilus* NCFM, *Lactobacillus paracasei* Lpc-37, *Bifidobacterium lactis* Bi-04, *Bifidobacterium lactis* Bi-07, and *Bifidobacterium bifidum* Bb-02. Developed by Aché Laboratórios Farmacêuticos in collaboration with the Universidade Federal de Alfenas, the therapy is designed to modulate the gut-brain axis to address neurodegenerative conditions. Administered orally, the blend aims to reshape the gut microbiota and subsequently influence systemic inflammatory and neurotrophic markers. Clinical investigations in older adults have demonstrated that the product can modulate levels of tumor necrosis factor-alpha (TNF-α), glial cell-derived neurotrophic factor (GDNF), and nerve growth factor (NGF), suggesting a potential therapeutic role in managing mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Other names: Aché probiotic blendFive-strain probiotic blend (Aché/UNIFAL)

Beyond the preview

Go deeper on lactobacillus acidophilus NCFM + lactobacillus paracasei Lpc-37 + bifidobacterium lactis Bi-04 + bifidobacterium lactis Bi-07 + bifidobacterium bifidum Bb-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus NCFM + lactobacillus paracasei Lpc-37 + bifidobacterium lactis Bi-04 + bifidobacterium lactis Bi-07 + bifidobacterium bifidum Bb-02.

Explore the full profile